Neuroendocrine tumours

Endocrine-Related Cancer

Volumn 11, Issue 1, 2004, Pages 1-18

  Barakat, M T ^a   Meeran, K ^a   Bloom, S R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANREOTIDE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTATE[3 TYROSINE] LU 177; ALPHA INTERFERON; ANGIOPEPTIN; ANTICOAGULANT AGENT; BICARBONATE; BISPHOSPHONIC ACID DERIVATIVE; CARBOHYDRATE; CHROMOGRANIN A; CISPLATIN; CYPROHEPTADINE; DIAZOXIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLUCOSE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; INSULIN; LOMUSTINE; NEUTRALIZING ANTIBODY; NICOTINAMIDE; OCTREOTIDE; PANCREAS ENZYME; PENTETREOTIDE IN 111; POTASSIUM; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY PRODUCTION; ARTIFICIAL EMBOLISM; AUTOIMMUNE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURGERY; CARCINOGENESIS; CARCINOID; CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC IMAGING; DRUG MEGADOSE; FATIGUE; FLU LIKE SYNDROME; GENETIC SCREENING; HORMONE SYNTHESIS; HUMAN; INOPERABLE CANCER; INTERVENTIONAL RADIOLOGY; LIVER TOXICITY; METASTASIS; MORBIDITY; MULTIPLE ENDOCRINE NEOPLASIA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NEUROFIBROMATOSIS; NEUROMODULATION; NEUROSECRETORY CELL; PALLIATIVE THERAPY; PANCREAS ISLET CELL TUMOR; PHENOTYPE; PHEOCHROMOCYTOMA; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SIPPLE SYNDROME; SYMPTOM; WEIGHT REDUCTION;

CARCINOID TUMOR; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMORS; PHEOCHROMOCYTOMA; SYNDROME; TUMOR MARKERS, BIOLOGICAL;

EID: 1842577499     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0110001     Document Type: Review

References (141)

1. Adams S & Baum RP 2000 Intraoperative use of gamma-detecting probes to localize neuroendocrine tumors. Quarterly Journal of Nuclear Medicine 44 59-67.
2. Ajani JA, Carrasco CH, Charnsangavej C, Samaan NA, Levin B & Wallace S 1988 Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Annals of Internal Medicine 108 340-344.
3. Aldridge MC & Williamson RCN 1993 Surgery of Endocrine Tumours of the Pancreas. In Surgical Endocrinology, pp 503-520. Eds J Lynn & SR Bloom. Oxford: Butterworth-Heinemann Ltd.
4. Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD & Shapiro B 1994 Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. Journal of Nuclear Medicine 35 1637-1644.
5. Arafah BM & Nasrallah MP 2001 Pituitary tumors: pathophysiology, clinical manifestations and management. Endocrine-Related Cancer 8 287-305.
6. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jurgensen R, Stein K, Schafer H, Bruns C & Dennler HJ 1996 Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38 430-438.
7. Arnold R, Simon B & Wied M 2000 Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 62 (Suppl 1) 84-91.
8. Ashrafian H, Taylor-Robinson SD, Calam J & Playford RJ 2002 Once you start, you can't stop. Lancet 359 226.
9. Bardeesy N, Sinha M, Hezel AF, Signoretti S, Hathaway NA, Sharpless NE, Loda M, Carrasco DR & DePinho RA 2002 Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 419 162-167.
10. di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, Zilembo N & di Leo A 1996 Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77 402-408.
11. Bechstein WO & Neuhaus P 1994 Liver transplantation for hepatic metastases of neuroendocrine tumors. Annals of the New York Academy of Sciences 733 507-514.
12. Behr TM & Behe MP 2002 Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Seminars in Nuclear Medicine 32 97-109.
13. Bergeron F, Leduc R & Day R 2000 Subtilase-like pro-protein convertases: from molecular specificity to therapeutic applications. Journal of Molecular Endocrinology 24 1-22.
14. Bilchik AJ, Sarantou T, Foshag LJ, Giuliano AE & Ramming KP 1997 Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 122 1040-1047.
15. Bouloux PG 2002 Phaeochromocytomas and paragangliomas. In Endocrinology Specialist Handbook, pp 447-469. Eds K Meeran & S Robinson. London: Martin Dunitz Ltd.
16. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr & Marx SJ 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal Clinical Endocrinology and Metabolism 86 5658-5671.
17. Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM, Bell GI, Schally AV, Vaysse N & Susini C 1995 Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. PNAS 92 1580-1584.
18. Bystrom C, Larsson C, Blomberg C, Sandelin K, Falkmer U, Skogseid B, Oberg K, Werner S & Nordenskjold M 1990 Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors. PNAS 87 1968-1972.
19. Calender A 2000 Molecular genetics of neuroendocrine tumors. Digestion 62 (Suppl 1) 3-18.
20. Capella C, Heitz PU, Hofler H, Solcia E & Kloppel G 1994 Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Digestion 55 (Suppl 3) 11-23.
21. Carrasco CH, Chuang VP & Wallace S 1983 APUDomas metastatic to the liver: treatment by hepatic artery embolization. Radiology 149 79-83.
22. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y & Blumgart LH 2000 Hepatic neuroendocrine metastases: does intervention alter outcomes? Journal of the American College of Surgeons 190 432-445.
23. Chen H, Hardacre JM, Uzar A, Cameron JL & Choti MA 1998 Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? Journal of the Americal College of Surgeons 187 88-92.
24. Day R & Salzet M 2002 The neuroendocrine phenotype, cellular plasticity, and the search for genetic switches: redefining the diffuse neuroendocrine system. Neuroendocrinology Letters 23 447-451.
25. Doppman JL, Miller DL, Chang R, Maton PN, London JF, Gardner JD, Jensen RT & Norton JA 1990 Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology 174 25-29.
26. Doppman JL, Miller DL, Chang R, Shawker TH, Gorden P & Norton JA 1991 Insulinomas: localization with selective intraarterial injection of calcium. Radiology 178 237-241.
27. Emmert-Buck MR, Lubensky IA, Dong Q, Manickam P, Guru SC, Kester MB, Olufemi SE, Agarwal S, Burns AL, Spiegel AM, Collins FS, Marx SJ, Zhuang Z, Liotta LA, Chandrasekharappa SC & Debelenko LV 1997 Localization of the multiple endocrine neoplasia type I (MEN1) gene based on tumor loss of heterozygosity analysis. Cancer Research 57 1855-1858.
28. Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Ponder MA & Ponder BA 1995 Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clinical Endocrinology 43 123-127.
29. Eriksson B & Oberg K 1993 An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncology 32 203-208.
30. Eriksson B, Arnberg H, Lindgren PG, Lorelius LE, Magnusson A, Lundqvist G, Skogseid B, Wide L, Wilander E & Oberg K 1990 Neuroendocrine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients. Journal of Internal Medicine 228 103-113.
31. Eriksson B, Renstrup J, Imam H & Oberg K 1997 High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Annals of Oncology 8 1041-1044.
32. Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE & Oberg KE 1998 Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83 2293-2301.
33. Eriksson B, Bergstrom M, Orlefors H, Sundin A, Oberg K & Langstrom B 2000 Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Quarterly Journal of Nuclear Medicine 44 68-76.
34. Eriksson B, Bergstrom M, Sundin A, Juhlin C, Orlefors H, Oberg K & Langstrom B 2002 The role of PET in localization of neuroendocrine and adrenocortical tumors. Annals of the New York Academy of Sciences 970 159-169.
35. European Neuroendocrine Tumor Network (ENET) 2000 Role of somatostatin analogues in oncology. Round Table Discussion: Innsbruck, Austria, February 24-27 2000. Digestion 62 (Suppl 1) 98-107.
36. Faiss S, Rath U, Mansmann U, Caird D, Clemens N, Riecken EO & Wiedenmann B 1999 Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 60 469-476.
37. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, Riecken EO & Wiedenmann B 2003 Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. Journal of Clinical Oncology 21 2689-2696.
38. Fearon ER & Vogelstein B 1990 A genetic model for colorectal tumorigenesis. Cell 61 759-767.
39. Fedorak IJ, Ko TC, Gordon D, Flisak M & Prinz RA 1993 Localization of islet cell tumors of the pancreas: a review of current techniques. Surgery 113 242-249.
40. Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET & Eriksson BK 2001 Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92 1101-1107.
41. Friesen SR 1987 Update on the diagnosis and treatment of rare neuroendocrine tumors. Surgical Clinic of North America 67 379-393.
42. Frucht H, Howard JM, Slaff JI, Wank SA, McCarthy DM, Maton PN, Vinayek R, Gardner JD & Jensen RT 1989 Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study. Annals of Internal Medicine 111 713-722.
43. Gilligan CJ, Lawton GP, Tang LH, West AB & Modlin IM 1995 Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. American Journal of Gastroenterology 90 338-352.
44. Glover JR, Shorvon PJ & Lees WR 1992 Endoscopic ultrasound for localisation of islet cell tumours. Gut 33 108-110.
45. Goldstone AP, Scott-Coombes DM & Lynn JA 1996 Surgical management of gastrointestinal endocrine tumours. Baillieres Clinical Gastroenterology 10 707-736.
46. Hamid QA, Bishop AE, Sikri KL, Varndell IM, Bloom SR & Polak JM 1986 Immunocytochemical characterization of 10 pancreatic tumours, associated with the glucagonoma syndrome, using antibodies to separate regions of the pro-glucagon molecule and other neuroendocrine markers. Histopathology 10 119-133.
47. de Herder WW & Lamberts SW 2002 Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Current Opinion in Oncology 14 53-57.
48. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM & Baylin SB 1994 Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. PNAS 91 9700-9704.
49. Jaeck D, Oussoultzoglou E, Bachellier P, Lemarque P, Weber JC, Nakano H & Wolf P 2001 Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World Journal of Surgery 25 689-692.
50. Jakobovitz O, Nass D, DeMarco L, Barbosa AJ, Simoni FB, Rechavi G & Friedman E 1996 Carcinoid tumors frequently display genetic abnormalities involving chromosome 11. Journal of Clinical Endocrinology and Metabolism 81 3164-3167.
51. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E & Oberg K 1997 Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Annals of Oncology 8 685-690.
52. Jensen RT 2001 Endocrine tumors of the gastrointestinal tract and pancreas. In Harrison's Principles of Internal Medicine, edn 15, pp 593-603. Eds E Braunwald, AS Fauci, DL Kasper, SL Hauser, DL Longo & JL Jameson. New York: McGraw-Hill.
53. de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, Visser TJ, Jermann E, Behe M, Powell P & Macke HR 1997 Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,D-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. European Journal of Nuclear Medicine 24 368-371.
54. Kaltsas GA, Mukherjee JJ, Isidori A, Kola B, Plowman PN, Monson JP, Grossman AB & Besser GM 2002 Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil. Clinical Endocrinology 57 169-183.
55. de Kerviler E, Cadiot G, Lebtahi R, Faraggi M, Le Guludec D & Mignon M 1994 Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. GRESZE: Groupe d'Etude du Syndrome de Zollinger-Ellison. European Journal of Nuclear Medicine 21 1191-1197.
56. Kimura W, Kuroda A & Morioka Y 1991 Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Digestive Diseases and Sciences 36 933-942.
57. Kloppel G & Heitz PU 1988 Pancreatic endocrine tumors. Pathology, Research and Practice 183 155-168.
58. Kloppel G & Heitz PU 1994 Classification of normal and neoplastic neuroendocrine cells. Annals of the New York Academy of Sciences 733 19-23.
59. Knudson AG Jr 1971 Mutation and cancer: statistical study of retinoblastoma. PNAS 68 820-823.
60. Kouvaraki MA, Lee JE, Shapiro SE, Gagel RF, Sherman SI, Sellin RV, Cote GJ & Evans DB 2002 Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Archives in Surgery 137 641-647.
61. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC, Visser TJ, Reis AEM, Hofland LT, Koper JW & Lamberts SWJ 1993 Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. European Journal of Nuclear Medicine 20 716-731.
62. Kwekkeboom DJ & Krenning EP 2002 Somatostatin receptor imaging. Seminars in Nuclear Medicine 32 84-91.
63. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Feelders RA, Van Eijck CH, de Jong M, Srinivasan A, Erion JL & Krenning EP 2003 Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0), Tyr(3)]octreotate. European Journal of Nuclear Medicine and Molecular Imaging 30 417-422.
64. Langley K 1994 The neuroendocrine concept today. Annals of the New York Academy of Sciences 733 1-17.
65. Larsson C, Skogseid B, Oberg K, Nakamura Y & Nordenskjold M 1988 Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332 85-87.
66. Lauffer JM, Zhang T & Modlin IM 1999 Review article: current status of gastrointestinal carcinoids. Alimentary Pharmacology and Therapeutics 13 271-287.
67. Le Douarin NM 1988 On the origin of pancreatic endocrine cells. Cell 53 169-171.
68. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, Mignon M & Le Guludec D 1997 Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. Journal of Nuclear Medicine 38 853-858.
69. Legaspi A & Brennan MF 1988 Management of islet cell carcinoma. Surgery 104 1018-1023.
70. Leimer M, Kurtaran A, Smith-Jones P, Raderer M, Havlik E, Angelberger P, Vorbeck F, Niederle B, Herold C & Virgolini I 1998 Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. Journal of Nuclear Medicine 39 2090-2094.
71. Lightdale CJ, Botet JF, Woodruff JM & Brennan MF 1991 Localization of endocrine tumors of the pancreas with endoscopic ultrasonography. Cancer 68 1815-1820.
72. Lubensky IA, Debelenko LV, Zhuang Z, Emmert-Buck MR, Dong Q, Chandrasekharappa S, Guru SC, Manickam P, Olufemi SE, Marx SJ, Spiegel AM, Collins FS & Liotta LA 1996 Allelic deletions on chromosome 11q13 in multiple tumors from individual MEN1 patients. Cancer Research 56 5272-5278.
73. McGuigan JE & Wolfe MM 1980 Secretin injection test in the diagnosis of gastrinoma. Gastroenterology 79 1324-1331.
74. McStay MK & Caplin ME 2002 Carcinoid tumour. Minerva Medicine 93 389-401.
75. Marx SJ, Agarwal SK, Kester MB, Heppner C, Kim YS, Emmert-Buck MR, Debelenko LV, Lubensky IA, Zhuang Z, Guru SC, Manickam P, Olufemi SE, Skarulis MC, Doppman JL, Alexander RH, Liotta LA, Collins FS, Chandrasekharappa SC, Spiegel AM & Burns AL 1998 Germline and somatic mutation of the gene for multiple endocrine neoplasia type 1 (MEN1). Journal of Internal Medicine 243 447-453.
76. Marx SJ, Agarwal SK, Kester MB, Heppner C, Kim YS, Skarulis MC, James LA, Goldsmith PK, Saggar SK, Park SY, Spiegel AM, Burns AL, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Emmert-Buck MR, Guru SC, Manickam P, Crabtree J, Erdos MR, Collins FS & Chandrasekharappa SC 1999 Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Progress in Hormone Research 54 397-438.
77. Modlin IM & Sandor A 1997 An analysis of 8305 cases of carcinoid tumors. Cancer 79 813-829.
78. Modlin IM & Tang LH 1997 Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Gastroenterology 112 583-590.
79. Modlin IM, Lye KD & Kidd M 2003 A 5-decade analysis of 13 715 carcinoid tumors. Cancer 97 934-959.
80. Moertel CG, Kvols LK, O'Connell MJ & Rubin J 1991 Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68 227-232.
81. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG & Klaassen D 1992 Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine 326 519-523.
82. Moertel CG, Johnson CM, McKusick MA, Martin JK Jr, Nagorney DM, Kvols LK, Rubin J & Kunselman S 1994 The management of patients with advanced carcinoid tumors and islet cell carcinomas. Annals of Internal Medicine 120 302-309.
83. Moller JE, Connolly HM, Rubin J, Seward JB, Modesto K & Pellikka PA 2003 Factors associated with progression of carcinoid heart disease. New England Journal of Medicine 348 1005-1015.
84. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C & Eng C 2002 Germ-line mutations in nonsyndromic pheochromocytoma. New England Journal of Medicine 346 1459-1466.
85. Norheim I, Theodorsson-Norheim E, Brodin E & Oberg K 1986 Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush. Journal of Clinical Endocrinology and Metabolism 63 605-612.
86. Oberg K 2000 Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 62 (Suppl 1) 92-97.
87. Oberg K & Eriksson B 1991 The role of interferons in the management of carcinoid tumors. Acta Oncology 30 519-522.
88. Oberg K & Skogseid B 1998 The ultimate biochemical diagnosis of endocrine pancreatic tumours in MEN-1. Journal of Internal Medicine 243 471-476.
89. Oberg K, Funa K & Alm G 1983 Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. New England Journal of Medicine 309 129-133.
90. O'Shea D, Rohrer-Theurs AW, Lynn JA, Jackson JE & Bloom SR 1996 Localization of insulinomas by selective intraarterial calcium injection. Journal of Clinical Endocrinology and Metabolism 81 1623-1627.
91. Palazzo L, Roseau G & Salmeron M 1992 Endoscopic ultrasonography in the preoperative localization of pancreatic endocrine tumors. Endoscopy 24 (Suppl 1) 350-353.
92. Pannett AA & Thakker RV 2001 Somatic mutations in MEN type I tumors, consistent with the Knudson 'two-hit' hypothesis. Journal of Clinical Endocrinology and Metabolism 86 4371-4374.
93. Patel YC & Srikant CB 1994 Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 135 2814-2817.
94. Pearse AG 1968 Common cytochemical and ultrastructural characteristics of cells producing polypeptide hormones (the APUD series) and their relevance to thyroid and ultimobranchial C cells and calcitonin. Proceedings of the Royal Society of London. Series B: Biological Sciences 170 71-80.
95. Pearse AG 1969 The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. Journal of Histochemistry and Cytochemistry 17 303-313.
96. Phillips TJ & Belknap JK 2002 Complex-trait genetics: emergence of multivariate strategies. Nature Reviews. Neuroscience 3 478-485.
97. Polak JM & Bloom SR 1979 The diffuse neuroendocrine system. Studies of this newly discovered controlling system in health and disease. Journal of Histochemistry and Cytochemistry 27 1398-1400.
98. Polak JM & Bloom SR 1986a Regulatory peptides of the gastrointestinal and respiratory tracts. Archives Internationales de Pharmacodynamie et de Therapie 280 16-49.
99. Polak JM & Bloom SR 1986b Somatostatin localization in tissues. Scandinavian Journal of Gastroenterology 119 (Suppl) 11-21.
100. Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F, Affara NA & Maher ER 1997 Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. American Journal of Human Genetics 60 765-771.
101. Que FG, Nagorney DM, Batts KP, Linz LJ & Kvols LK 1995 Hepatic resection for metastatic neuroendocrine carcinomas. American Journal of Surgery 169 36-42.
102. Reisine T & Bell GI 1995 Molecular biology of somatostatin receptors. Endocrine Reviews 16 427-442.
103. Ricke J, Klose KJ, Mignon M, Oberg K & Wiedenmann B 2001 Standardisation of imaging in neuroendocrine tumours: results of a European Delphi process. European Journal of Radiology 37 8-17.
104. Rindi G, Capella C & Solcia E 1998 Cell biology, clinicopathological profile, and classification of gastroenteropancreatic endocrine tumors. Journal of Molecular Medicine 76 413-420.
105. Rosch T, Lightdale CJ, Botet JF, Boyce GA, Sivak MV Jr, Yasuda K, Heyder N, Palazzo L, Dancygier H, Schusdziarra V & Lassen M 1992 Localization of pancreatic endocrine tumors by endoscopic ultrasonography. New England Journal of Medicine 326 1721-1726.
106. Rougier P & Mitry E 2000 Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 62 (Suppl 1) 73-78.
107. Ruszniewski P & Malka D 2000 Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion 62 (Suppl 1) 79-83.
108. Ruszniewski P, Amouyal P, Amouyal G, Grange JD, Mignon M, Bouche O & Bernades P 1995 Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery 117 629-635.
109. Sandler M & Snow P 1958 An atypical carcinoid tumour secreting 5-hydroxytryptophan. Lancet 1 139.
110. Sapin R 2003 Insulin assays: previously known and new analytical features. Clinical Laboratory 49 113-121.
111. Schindl M, Kaczirek K, Kaserer K & Niederle B 2000 Is the new classification of neuroendocrine pancreatic tumors of clinical help? World Journal of Surgery 24 1312-1318.
112. Sekiya K, Ghatei MA, Salahuddin MJ, Bishop AE, Hamid QA, Ibayashi H, Polak JM & Bloom SR 1989 Production of GAWK (chromogranin-B 420-493)-like immunoreactivity by endocrine tumors and its possible diagnostic value. Journal of Clinical Investigation 83 1834-1842.
113. Service FJ 1995 Hypoglycemic disorders. New England Journal of Medicine 332 1144-1152.
114. Service FJ & Natt N 2000 The prolonged fast. Journal of Clinical Endocrinology and Metabolism 85 3973-3974.
115. Shannon BA & Iacopetta BJ 2001 Methylation of the hMLH1, p16, and MDR1 genes in colorectal carcinoma: associations with clinicopathological features. Cancer Letters 167 91-97.
116. Snow P, Lennard-Jones J, Curzon G & Stacey RS 1955 Humoral effects of metastasising carcinoid tumours. Lancet 269 1004-1009.
117. Solcia E, Sessa F, Rindi G, Villani L, Riva C, Buffa R & Capella C 1990 Classification and histogenesis of gastroenteropancreatic endocrine tumours. European Journal of Clinical Investigation 20 (Suppl 1) 72-81.
118. Solcia E, Kloppel G & Sobin LH 2000 World Health Organization International Histological Classification of Endocrine Tumours. Histological Typing of Endocrine Tumours 2nd edn.
119. Stokes KR, Stuart K & Clouse ME 1993 Hepatic arterial chemoembolization for metastatic endocrine tumors. Journal of Vascular and Interventional Radiology 4 341-345.
120. Stridsberg M, Oberg K, Li Q, Engstrom U & Lundqvist G 1995 Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. Journal of Endocrinology 144 49-59.
121. Taheri S & Meeran K 2002 Gut hormones and gut hormone tumours. In Endocrinology Specialist Handbook, pp 295-310. Eds K Meeran & S Robinson. London: Martin Dunitz Ltd.
122. Taheri S, Ghatei MA & Bloom SR 2001 Gastrointestinal Hormones and Tumor Syndromes. In Endocrinology, 4th edn, pp 2547-2558. Eds LJ De Groot & JL Jameson. Philadelphia: WB Saunders.
123. Tapia FJ, Polak JM, Barbosa AJ, Bloom SR, Marangos PJ, Dermody C & Pearse AG 1981 Neuron-specific enolase is produced by neuroendocrine tumours. Lancet 1 808-811.
124. Taupenot L, Harper KL & O'Connor DT 2003 The chromogranin-secretogranin family. New England Journal of Medicine 348 1134-1149.
125. Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, Sutliff VE & Jensen RT 1997 Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 112 335-347.
126. Thakker RV, Bouloux P, Wooding C, Chotai K, Broad PM, Spurr NK, Besser GM & O'Riordan JL 1989 Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. New England Journal of Medicine 321 218-224.
127. Thompson NW, Czako PF, Fritts LL, Bude R, Bansal R, Nostrant TT & Scheiman JM 1994 Role of endoscopic ultrasonography in the localization of insulinomas and gastrinomas. Surgery 116 1131-1138.
128. Tiensuu JE, Eriksson B, Oberg K, Skogseid B, Ohrvall U, Nilsson S & Westlin JE 1999 Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors - evaluation of therapeutic and toxic effects. Acta Oncology 38 373-377.
129. Todd JF & Bloom SR 2002 Insulinomas and hypoglycaemia. In Oxford Textbook of Endocrinology and Diabetes, Eds JAH Wass & SM Shalet. Oxford: Oxford University Press.
130. Turner JJ, Wren AM, Jackson JE, Thakker RV & Meeran K 2002 Localization of gastrinomas by selective intra-arterial calcium injection. Clinical Endocrinology 57 821-825.
131. Vinik AI 2001 Carcinoid Tumors. In Endocrinology, 4th edn, pp 2533-2546. Eds LJ De Groot & JL Jameson. Philadelphia: WB Saunders.
132. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G & Riva P 2002 In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Seminars in Nuclear Medicine 32 148-155.
133. Wallace S, Ajani JA, Charnsangavej C, DuBrow R, Yang DJ, Chuang VP, Carrasco CH & Dodd GD Jr 1996 Carcinoid tumors: imaging procedures and interventional radiology. World Journal of Surgery 20 147-156.
134. Warner RR & O'dorisio TM 2002 Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. Seminars in Nuclear Medicine 32 79-83.
135. Winkler H & Fischer-Colbrie R 1992 The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 49 497-528.
136. Wood SM, Polak JM & Bloom SR 1983 Gut hormone secreting tumours. Scandinavian Journal of Gastroenterology 82 (Suppl) 165-179.
137. Wulbrand U, Wied M, Zofel P, Goke B, Arnold R & Fehmann H 1998 Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. European Journal of Clinical Investigation 28 1038-1049.
138. Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, Benson AB, Rao S & Joehl RJ 2001 Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 130 677-682.
139. Yasuda D, Iguchi H, Funakoshi A, Wakasugi H, Sekiya K, Misawa T, Tateishi K, Bloom SR & Nawata H 1993 Comparison of plasma pancreastatin and GAWK concentrations, presumed processing products of chromogranin A and B, in plasma of patients with pancreatic islet cell tumors. Hormone and Metabolic Research 25 593-595.
140. Yiangou Y, Williams SJ, Bishop AE, Polak JM & Bloom SR 1987 Peptide histidine-methionine immunoreactivity in plasma and tissue from patients with vasoactive intestinal peptide-secreting tumors and watery diarrhea syndrome. Journal of Clinical Endocrinology and Metabolism 64 131-139.
141. Zimmer T, Scherubl H, Faiss S, Stolzel U, Riecken EO & Wiedenmann B 2000 Endoscopic ultrasonography of neuroendocrine tumours. Digestion 62 (Suppl 1) 45-50.